CNBX (CNBX Pharmaceuticals) EBITDA Margin %: 0.00% (As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is CNBX Pharmaceuticals EBITDA Margin %?

CNBX Pharmaceuticals CNBX +33.33% EBITDA Margin % is 0.00% as of May. 2026. The stock has 3 warning signs investors should review. Among 942 Biotechnology companies, CNBX Pharmaceuticals ranks worse than 106157.01% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. CNBX Pharmaceuticals's EBITDA for the three months ended in May. 2026 was $-0.16 Mil. CNBX Pharmaceuticals's Revenue for the three months ended in May. 2026 was $0.00 Mil. Therefore, CNBX Pharmaceuticals's EBITDA margin for the quarter that ended in May. 2026 was 0.00%.

CNBX Pharmaceuticals  (OTCPK:CNBX) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

CNBX Pharmaceuticals EBITDA Margin % Related Terms

CNBX Pharmaceuticals EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for CNBX Pharmaceuticals's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CNBX Pharmaceuticals EBITDA Margin % Chart

CNBX Pharmaceuticals Annual Data
Trend Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -13,976.67 -865.12 -463.85 0.00

CNBX Pharmaceuticals Quarterly Data
Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CNBX vs SIGY, LIPO, CARM: EBITDA Margin % Comparison

For the Biotechnology subindustry, CNBX Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CNBX Pharmaceuticals EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CNBX Pharmaceuticals's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where CNBX Pharmaceuticals's EBITDA Margin % falls into.


CNBX Pharmaceuticals EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

CNBX Pharmaceuticals's EBITDA Margin % for the fiscal year that ended in Aug. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Aug. 2025 )/Revenue (A: Aug. 2025 )
=-0.274/0
= %

CNBX Pharmaceuticals's EBITDA Margin % for the quarter that ended in May. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: May. 2026 )/Revenue (Q: May. 2026 )
=-0.163/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
CNBX Pharmaceuticals (CNBX) has a EBITDA Margin % of 0.00% as of May. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on CNBX Pharmaceuticals and its competitors. According to the industry distribution chart, CNBX Pharmaceuticals ranks #999999 out of 942 companies in the Biotechnology industry.
Is CNBX Pharmaceuticals' EBITDA Margin % too high?
CNBX Pharmaceuticals' current EBITDA Margin % is 0.00%. Based on the distribution chart, CNBX Pharmaceuticals ranks #999999 out of 942 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does CNBX Pharmaceuticals' EBITDA Margin % compare to SIGY and LIPO?
According to the Biotechnology industry distribution chart, CNBX Pharmaceuticals ranks #999999 out of 942 companies for EBITDA Margin %. This places CNBX Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on CNBX Pharmaceuticals and its competitors. CNBX Pharmaceuticals's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CNBX Pharmaceuticals stock overvalued right now?
CNBX Pharmaceuticals (CNBX) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For CNBX Pharmaceuticals (CNBX), the current EBITDA Margin % is 0.00% as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CNBX Pharmaceuticals Business Description

Address No. 3 Bethesda Metro Center, Suite 700, Bethesda, MD, USA, 20814
CNBX Pharmaceuticals Inc is a clinical-stage biotechnology company. It develops pharmaceuticals focusing on cancer research utilizing HTS technology and personalized bioinformatics tools. The company's main focus is the development of cannabinoid therapies and other technologies for the treatment of cancer, mainly cancers of the gastrointestinal tract, skin, breast, and prostate. The firm's main product is the Cannabics SR, an oral capsule developed for the treatment of patients with cancer and cancer anorexia cachexia syndrome (CACS). It also has an anti-neoplastic drug candidate under development for Colorectal Cancer (CRC) named RCC-33.